logoCabeceraNinos

Hemos leído sobre ... Miopatías inflamatorias

Última actualización: 05 diciembre 2016


NOVIEMBRE 2016
  • Ibarra M, Rigsby C, Morgan GA, Sammet CL, Huang CC, Xu D, Targoff IN, Pachman LM.
    Monitoring change in volume of calcifications in juvenile idiopathic inflammatory myopathy: a pilot study using low dose computed tomography.
    Pediatr Rheumatol Online J. 2016 Nov 29;14(1):64.
    https://www.ncbi.nlm.nih.gov/pubmed/27894310
  • Huber AM, Kim S, Reed AM, Carrasco R, Feldman BM, Hong SD, Kahn P, Rahimi H, Robinson AB, Vehe RK, Weiss JE, Spencer C; and the Juvenile Dermatomyositis Research Committee of the Childhood Arthritis and Rheumatology Research Alliance.
    Childhood Arthritis and Rheumatology Research Alliance Consensus Clinical Treatment Plans for Juvenile Dermatomyositis with Persistent Skin Rash.
    J Rheumatol. 2016 Nov 1.
    https://www.ncbi.nlm.nih.gov/pubmed/27803135
  • López De Padilla CM, Crowson CS, Hein MS, Pendegraft RS, Strausbauch MA, Niewold TB, Ernste FC, Peterson E, Baechler EC, Reed AM.
    Gene Expression Profiling in Blood and Affected Muscle Tissues Reveals Differential Activation Pathways in Patients with New-onset Juvenile and Adult Dermatomyositis.
    J Rheumatol. 2016 Nov 1.
    https://www.ncbi.nlm.nih.gov/pubmed/27803134

OCTUBRE 2016
  • Deakin CT, Yasin SA, Simou S, Arnold KA, Tansley SL, Betteridge ZE, McHugh NJ, Varsani H, Holton JL, Jacques TS, Pilkington CA, Nistala K, Wedderburn LR; UK Juvenile Dermatomyositis Research Group..
    Muscle Biopsy Findings in Combination With Myositis-Specific Autoantibodies Aid Prediction of Outcomes in Juvenile Dermatomyositis.
    Arthritis Rheumatol. 2016 Nov;68(11):2806-2816. doi: 10.1002/art.39753
    https://www.ncbi.nlm.nih.gov/pubmed/27214289

SEPTIEMBRE 2016

AGOSTO 2016
  • Tansley SL.
    Antibodies in juvenile-onset myositis.
    Curr Opin Rheumatol. 2016 Nov;28(6):645-650.
    http://www.ncbi.nlm.nih.gov/pubmed/27533322
  • Speth F, Haas JP, Hinze CH.
    Treatment with high-dose recombinant human hyaluronidase-facilitated subcutaneous immune globulins in patients with juvenile dermatomyositis who are intolerant to intravenous immune globulins: a report of 5 cases.
    Pediatr Rheumatol Online J. 2016 Sep 13;14(1):52.
    http://www.ncbi.nlm.nih.gov/pubmed/27623619
  • Paik JJ, Christopher-Stine L.
    A case of refractory dermatomyositis responsive to tofacitinib
    Semin Arthritis Rheum 2016 Epub
    http://www.semarthritisrheumatism.com/article/S0049-0172(16)30200-1/abstract
  • Fotis L, Baszis KW, White AJ, French AR.
    Four Cases of Anti-PM/Scl Antibody-positive Juvenile Overlap Syndrome with Features of Myositis and Systemic Sclerosis.
    J Rheumatol. 2016 Sep;43(9):1768-9.
    http://www.ncbi.nlm.nih.gov/pubmed/27587018
  • Li T, Guo L, Chen Z, Gu L, Sun F, Tan X, Chen S, Wang X, Ye S.
    Pirfenidone in patients with rapidly progressive interstitial lung disease associated with clinically amyopathic dermatomyositis.
    Sci Rep. 2016 Sep 12;6:33226.
    http://www.ncbi.nlm.nih.gov/pubmed/27615411
  • Sato S, Uejima Y, Nanbu M, Suganuma E, Takano T, Tanaka R, Kabuki T, Oguma E, Oh-Ishi T, Kawano Y.
    Clinical analysis and outcome of interstitial lung disease complicated with juvenile dermatomyositis and juvenile polymyositis.
    Mod Rheumatol. 2016 Sep 20:1-5. [Epub ahead of print]
    http://www.ncbi.nlm.nih.gov/pubmed/27588444

JUNIO 2016
  • Leverenz D, Zaha O, Crofford LJ, Chung CP.
    Causes of creatine kinase levels greater than 1000 IU/L in patients referred to rheumatology.
    Clin Rheumatol. 2016 Jun;35(6):1541-7. doi: 10.1007/s10067-016-3242-9.
    http://www.ncbi.nlm.nih.gov/pubmed/27041384

ABRIL 2016
  • Preuße C, Allenbach Y, Hoffmann O, Goebel HH, Pehl D, Radke J, Doeser A, Schneider U, Alten RH, Kallinich T, Benveniste O, von Moers A, Schoser B, Schara U, Stenzel W.
    Differential roles of hypoxia and innate immunity in juvenile and adult dermatomyositis.
    Acta Neuropathol Commun. 2016 Apr 27;4(1):45. doi: 10.1186/s40478-016-0308-5.
    http://www-ncbi-nlm-nih-gov.sire.ub.edu/pubmed/27121733
  • Pinto AJ, Yazigi Solis M, de Sá Pinto AL, Silva CA, Maluf Elias Sallum A, Roschel H, Gualano B.
    Physical (in)activity and its influence on disease-related features, physical capacity, and health-related quality of life in a cohort of chronic juvenile dermatomyositis patients.
    Semin Arthritis Rheum. 2016 Mar 18. pii: S0049-0172(16)00102-5. doi: 10.1016/j.semarthrit.2016.03.010. 
    http://www-ncbi-nlm-nih-gov.sire.ub.edu/pubmed/27113390

MARZO 2016
  • Rider LG, Nistala K.
    The juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes, and outcomes.
    J Intern Med. 2016 Mar 30. doi: 10.1111/joim.12444. [Epub ahead of print]
    http://www.ncbi.nlm.nih.gov/pubmed/27028907
  • de Inocencio J, Enríquez-Merayo E, Casado R, González-Granado LI.
    Subcutaneous Immunoglobulin in Refractory Juvenile Dermatomyositis.
    Pediatrics. 2016 Mar 10. pii: peds.2015-3537. [Epub ahead of print]
    http://www.ncbi.nlm.nih.gov/pubmed/26966131
  • Salman A, Kasapcopur O, Ergun T, Durmus Ucar AN, Demirkesen C.
    Panniculitis in juvenile dermatomyositis: Report of a case and review of the published work.
    J Dermatol. 2016 Mar 12. doi: 10.1111/1346-8138.13335. [Epub ahead of print]
    http://www.ncbi.nlm.nih.gov/pubmed/26971888
  • Saini I, Kalaivani M, Kabra SK.
    Calcinosis in juvenile dermatomyositis: frequency, risk factors and outcome.
    Rheumatol Int. 2016 Mar 23. [Epub ahead of print]
    http://www.ncbi.nlm.nih.gov/pubmed/27007612
  • Habers GE, Bos GJ, van Royen-Kerkhof A, Lelieveld OT, Armbrust W, Takken T, van Brussel M.
    Muscles in motion: a randomized controlled trial on the feasibility, safety and efficacy of an exercise training programme in children and adolescents with juvenile dermatomyositis.
    Rheumatology (Oxford). 2016 Mar 27. pii: kew026. [Epub ahead of print]
    http://www.ncbi.nlm.nih.gov/pubmed/27018060
  • Pinto AJ, Roschel H, Benatti FB, de Sá Pinto AL, Sallum AM, Silva CA, Gualano B.
    Poor agreement of objectively measured and self-reported physical activity in juvenile dermatomyositis and juvenile systemic lupus erythematosus.
    Clin Rheumatol. 2016 Mar 28. [Epub ahead of print]
    http://www.ncbi.nlm.nih.gov/pubmed/27021334

FEBRERO 2016
  • Campanilho-Marques R, Almeida B, Deakin C, Arnold K, Gallot N, de Iorio M, Nistala K, Pilkington CA, Wedderburn LR; Juvenile Dermatomyositis Research Group (JDRG).
    Comparison of the utility and validity of three scoring tools to measure skin involvement in patients with Juvenile Dermatomyositis.
    Arthritis Care Res (Hoboken). 2016 Feb 16. doi: 10.1002/acr.22867. [Epub ahead of print]
    http://www.ncbi.nlm.nih.gov/pubmed/26881696
  • Alexanderson H.
    Physical exercise as a treatment for adult and juvenile myositis.
    J Intern Med. 2016 Feb 8. doi: 10.1111/joim.12481. [Epub ahead of print]
    http://www.ncbi.nlm.nih.gov/pubmed/26854121
  • Ruperto N, Pistorio A, Oliveira S, Zulian F, Cuttica R, Ravelli A, Fischbach M, Magnusson B, Sterba G, Avcin T, Brochard K, Corona F, Dressler F, Gerloni V, Apaz MT, Bracaglia C, Cespedes-Cruz A, Cimaz R, Couillault G, Joos R, Quartier P, Russo R, Tardieu M, Wulffraat N,Bica B, Dolezalova P, Ferriani V, Flato B, Bernard-Medina AG, Herlin T, Trachana M, Meini A, Allain-Launay E, Pilkington C, Vargova V,Wouters C, Angioloni S, Martini A; Paediatric Rheumatology International Trials Organisation (PRINTO).
    Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial.
    Lancet. 2016 Feb 13;387(10019):671-8. doi: 10.1016/S0140-6736(15)01021-1. Epub 2015 Nov 30.
    http://www.ncbi.nlm.nih.gov/pubmed/26645190

NOVIEMBRE 2015
  • G Esther A Habers, Adam M Huber, Gulnara Mamyrova, Ira N Targoff, Terrance P O'Hanlon, Sharon Adams, Janardan P Pandey, Chantal Boonacker, Marco van Brussel, Frederick W Miller, Annet van Royen-Kerkhof, Lisa G Rider and Childhood Myositis Heterogeneity Study Group
    Myositis autoantibodies, clinical features, and environmental exposures at illness onset are associated with disease course in juvenile myositis

    Arthritis & Rheumatology DOI: 10.1002/art.39466
    Abstract
  • Tansley, Sarah; Wedderburn, Lucy R.
    Comparing and contrasting clinical and serological features of juvenile and adult-onset myositis: implications for pathogenesis and outcomes

    Current Opinion in Rheumatology:
    November 2015 - Volume 27 - Issue 6 - p 601–607
    doi: 10.1097/BOR.0000000000000224 
  • Hiroyuki Wakiguchi, Shunji Hasegawa, Reiji Hirano, Hidenobu Kaneyasu, Midori Wakabayashi-Takahara, Shouichi Ohga
    Successful control of juvenile dermatomyositis-associated macrophage activation syndrome and interstitial pneumonia: distinct kinetics of interleukin-6 and -18 levels
    Pediatric Rheumatology 2015, 13:49 (18 November 2015)
    Abstract

OCTUBRE 2015
  • Habers GE, Huber AM, Mamyrova G, Targoff IN, O'Hanlon TP, Adams S, Pandey JP, Boonacker C, van Brussel M, Miller FW, van Royen-Kerkhof A, Rider LG; Childhood Myositis Heterogeneity Study Group.
    Myositis autoantibodies, clinical features, and environmental exposures at illness onset are associated with disease course in juvenile myositis.
    Arthritis Rheumatol. 2015 Oct 16. doi: 10.1002/art.39466.
    http://www.ncbi.nlm.nih.gov/pubmed/26474155
  • Tansley S, Wedderburn LR.
    Comparing and contrasting clinical and serological features of juvenile and adult-onset myositis: implications for pathogenesis and outcomes
    Curr Opin Rheumatol. 2015 Nov;27(6):601-7. doi: 10.1097/BOR.0000000000000224.
    http://www.ncbi.nlm.nih.gov/pubmed/26352731
  • Barth Z, Nomeland Witczak B, Schwartz T, Gjesdal K, Flatø B, Koller A, Sanner H, Sjaastad I.
    In juvenile dermatomyositis, heart rate variability is reduced, and associated with both cardiac dysfunction and markers of inflammation: a cross-sectional study median 13.5 years after symptom onset.
    Rheumatology (Oxford). 2015 Oct 24. pii: kev376. [Epub ahead of print]
    http://www.ncbi.nlm.nih.gov/pubmed/26500284
  • Pagnini I, Vitale A, Selmi C, Cimaz R, Cantarini L.
    Idiopathic Inflammatory Myopathies: an Update on Classification and Treatment with Special Focus on Juvenile Forms
    Clin Rev Allergy Immunol. 2015 Oct 1. [Epub ahead of print]
    http://www.ncbi.nlm.nih.gov/pubmed/26429707

SEPTIEMBRE 2015
  • Miller FW, Chen W, O'Hanlon TP, Cooper RG, Vencovsky J, Rider LG, Danko K, Wedderburn LR, Lundberg IE, Pachman LM, Reed AM, Ytterberg SR, Padyukov L, Selva-O'Callaghan A, Radstake TR, Isenberg DA, Chinoy H, Ollier WE, Scheet P, Peng B, Lee A, Byun J, Lamb JA, Gregersen PK, Amos CI.
    Genome-wide association study identifies HLA 8.1 ancestral haplotype alleles as major genetic risk factors for myositis phenotypes.
    Genes Immun. 2015 Oct;16(7):470-80. doi: 10.1038/gene.2015.28.
    http://www.ncbi.nlm.nih.gov/pubmed/26291516
  • Rothwell S, Cooper RG, Lundberg IE, Miller FW, Gregersen PK, Bowes J, Vencovsky J, Danko K, Limaye V, Selva-O'Callaghan A, Hanna MG, Machado PM, Pachman LM, Reed AM, Rider LG, Cobb J, Platt H, Molberg Ø, Benveniste O, Mathiesen P, Radstake T, Doria A, De Bleecker J, De Paepe B, Maurer B, Ollier WE, Padyukov L, O'Hanlon TP, Lee A, Amos CI, Gieger C, Meitinger T, Winkelmann J, Wedderburn LR, Chinoy H, Lamb JA; Myositis Genetics Consortium.
    Dense genotyping of immune-related loci in idiopathic inflammatory myopathies confirms HLA alleles as the strongest genetic risk factor and suggests different genetic background for major clinical subgroups.
    Ann Rheum Dis. 2015 Sep 11. pii: annrheumdis-2015-208119. doi: 10.1136/annrheumdis-2015-208119. [Epub ahead of print]
    http://www.ncbi.nlm.nih.gov/pubmed/26362759 

AGOSTO 2015
  • van Brussel M, van Oorschot JW, Schmitz JP, Nicolay K, van Royen-Kerkhof A, Takken T, Jeneson JA.
    Muscle Metabolic Responses During Dynamic In-Magnet Exercise Testing: A Pilot Study in Children with an Idiopathic Inflammatory Myopathy.
    Acad Radiol. 2015 Aug 7. doi:10.1016/j.acra.2015.06.013. EPUB
    ahead of print]
    http://www.ncbi.nlm.nih.gov/pubmed/26259546
  • Cañas CA, Bonilla-Abadía F, Mejía M, Tobón GJ.
    Recovery of Severe Muscular and Fascial Calcinosis After Treatment With Bisphosphonates in a Child With Juvenile Dermatomyositis.
    J Clin Rheumatol. 2015 Aug;21(5):267-9. doi:10.1097/RHU.0000000000000264.
    http://www.ncbi.nlm.nih.gov/pubmed/26203832
  • Almeida B, Campanilho-Marques R, Arnold K, Pilkington CA, Wedderburn LR, Nistala K; Juvenile Dermatomyositis Research Group.
    Analysis of Published Criteria for Clinically Inactive Disease in a Large Juvenile Dermatomyositis Cohort Shows That Skin Disease Is Underestimated.
    Arthritis Rheumatol. 2015 Sep;67(9):2495-502. doi:10.1002/art.39200.
    http://www.ncbi.nlm.nih.gov/pubmed/25988361

JUNIO 2015
  • Lightfoot AP, McArdle A, Jackson MJ, Cooper RG.
    In the idiopathic inflammatory myopathies (IIM), do reactive oxygen species (ROS) contribute to muscle weakness?
    Ann Rheum Dis. 2015 Jul;74(7):1340-1346. doi: 10.1136/annrheumdis-2014-207172. Review.
    http://www.ncbi.nlm.nih.gov/pubmed/26063809
  •  Iglesias E, Bou R, Torrente-Segarra V, Antón J.
    Importancia de un estudio basal completo en pacientes con diagnóstico de dermatomiositis juvenil
    An Pediatr (Barc). 2015 Jun;82(6):449-50. doi: 10.1016/j.anpedi.2015.01.011.
    http://www.ncbi.nlm.nih.gov/pubmed/25746608

MAYO 2015
  • Norimoto Kobayashi, Shunichiro Takezaki, Ichiro Kobayashi, Naomi Iwata, Masaaki Mori, Kazushige Nagai, Naoko Nakano, Mari Miyoshi, Noriko Kinjo, Takuji Murata, Kenji Masunaga, Hiroaki Umebayashi, Tomoyuki Imagawa, Kazunaga Agematsu, Shinji Sato, Masataka Kuwana, Masafumi Yamada, Shuji Takei, Shumpei Yokota, Kenichi Koike, and Tadashi Ariga
    Clinical and laboratory features of fatal rapidly progressive interstitial lung disease associated with juvenile dermatomyositis
    Rheumatology (2015) 54 (5): 784-791 doi:10.1093/rheumatology/keu385
    http://rheumatology.oxfordjournals.org/content/54/5/784.abstract


ABRIL 2015

MARZO 2015

FEBRERO 2015
  • Otero Rivas MM, Vicente Villa A, González Lara L, Suñol Capella M, Antón López J, González Enseñat MA.
    Panniculitis in juvenile dermatomyositis.
    Clin Exp Dermatol. 2015 Feb 16.
    http://www.ncbi.nlm.nih.gov/pubmed/25682744
  • Hung CH.
    Treatment and clinical outcome of juvenile dermatomyositis.
    Pediatr Neonatol. 2015 Feb;56(1):1-2.
    http://www.ncbi.nlm.nih.gov/pubmed/25487198

ENERO 2015
  • Varsani H, Charman SC, Li CK, Marie SK, Amato AA, Banwell B, Bove KE, Corse AM, Emslie-Smith AM, Jacques TS, Lundberg IE, Minetti C, Nennesmo I, Rushing EJ, Sallum AM, Sewry C, Pilkington CA, Holton JL, Wedderburn LR; UK Juvenile Dermatomyositis Research Group.
    Validation of a score tool for measurement of histological severity in juvenile dermatomyositis and association with clinical severity of disease.
    Ann Rheum Dis. 2015 Jan;74(1):204-10. doi: 10.1136/annrheumdis-2013-203396. Epub 2013 Sep 24.
    http://www.ncbi.nlm.nih.gov/pubmed/24064003

DICIEMBRE 2014

NOVIEMBRE 2014
  • Palaniappan P, Lionel AP, Kumar S.
    Successful treatment of calcinosis cutis in juvenile dermatomyositis with pamidronate.
    J Clin Rheumatol. 2014 Dec;20(8):454-5.
    http://www.ncbi.nlm.nih.gov/pubmed/?term=24996906
  • Hoeltzel MF, Oberle EJ, Robinson AB, Agarwal A, Rider LG.
    The presentation, assessment, pathogenesis, and treatment of calcinosis in juvenile dermatomyositis.
    Curr Rheumatol Rep. 2014 Dec;16(12):467.
    http://www.ncbi.nlm.nih.gov/pubmed/?term=25366934
  • Bailey EE, Fiorentino DF.
    Amyopathic dermatomyositis: definitions, diagnosis, and management.
    Curr Rheumatol Rep. 2014 Dec;16(12):465
    http://www.ncbi.nlm.nih.gov/pubmed/?term=25366932
  • Cappelletti C, Galbardi B, Kapetis D, Vattemi G, Guglielmi V, Tonin P, Salerno F, Morandi L, Tomelleri G, Mantegazza R, Bernasconi P.
    Autophagy, inflammation and innate immunity in inflammatory myopathies.
    PLoS One. 2014 Nov 3;9(11):e111490.
    http://www.ncbi.nlm.nih.gov/pubmed/?term=25365350
  • Singh S, Suri D, Aulakh R, Gupta A, Rawat A, Kumar RM.
    Mortality in children with juvenile dermatomyositis: two decades of experience from a single tertiary care centre in North India.
    Clin Rheumatol. 2014 Nov;33(11):1675-9.
    http://www.ncbi.nlm.nih.gov/pubmed/?term=25053380
  • Schwartz T, Sjaastad I, Flatø B, Vistnes M, Christensen G, Sanner H.
    In active juvenile dermatomyositis, elevated eotaxin and MCP-1 and cholesterol levels in the upper normal range are associated with cardiac dysfunction.
    Rheumatology (Oxford). 2014 Dec;53(12):2214-22.
    http://www.ncbi.nlm.nih.gov/pubmed/?term=24996906
  • Tansley SL, Betteridge ZE, Shaddick G, Gunawardena H, Arnold K, Wedderburn LR, McHugh NJ; Juvenile Dermatomyositis Research Group.
    Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset.
    Rheumatology (Oxford). 2014 Dec;53(12):2204-8.
    http://www.ncbi.nlm.nih.gov/pubmed/?term=24987158
  • Gerhold K, Becker MO.
    Nailfold capillaroscopy in juvenile rheumatic diseases: known measures, patterns and indications.
    Clin Exp Rheumatol. 2014 Nov-Dec;32 Suppl 86(6):183-8.
    http://www.ncbi.nlm.nih.gov/pubmed/?term=24960119
  • Pavlov-Dolijanovic SR, Vujasinovic Stupar NZ, Gavrilov N, Seric S.
    Lower extremity lipedema, upper extremity lipodystrophy and severe calcinosis complicating juvenile dermatomyositis.
    Rheumatol Int. 2014 Nov;34(11):1615-8.
    http://www.ncbi.nlm.nih.gov/pubmed/?term=24789670
  • Ernste FC, Reed AM.
    Recent advances in juvenile idiopathic inflammatory myopathies
    Curr Opin Rheumatol. 2014 Nov;26(6):671-8. doi: 10.1097/BOR.0000000000000103.
    http://www.ncbi.nlm.nih.gov/pubmed/25160931
OCTUBRE 2014
  • Kobayashi N, Takezaki S, Kobayashi I, Iwata N, Mori M, Nagai K, Nakano N, Miyoshi M, Kinjo N, Murata T, Masunaga K, Umebayashi H, Imagawa T, Agematsu K, Sato S, Kuwana M, Yamada M, Takei S, Yokota S, Koike K, Ariga T.
    Clinical and laboratory features of fatal rapidly progressive interstitial lung disease associated with juvenile dermatomyositis.
    Rheumatology (Oxford). 2014 Oct 6. pii: keu385. [Epub ahead of print]
    http://www.ncbi.nlm.nih.gov/pubmed/25288783 
  • Ernste, Floranne C.; Reed, Ann M.
    Recent advances in juvenile idiopathic inflammatory myopathies
    Current Opinion in Rheumatology. Nov 2014.
    doi: 10.1097/BOR.0000000000000103
    http://journals.lww.com/co-rheumatology/Abstract/2014/11000/Recent_advances_in_juvenile_idiopathic.12.aspx

SEPTIEMBRE 2014
  • Sanner H, Sjaastad I, FlatØ B.
    Disease activity and prognostic factors in juvenile dermatomyositis: a long-term follow-up study applying the Paediatric Rheumatology International Trials Organization criteria for inactive disease and the myositis disease activity assessment tool.
    Rheumatology (2014);53(9):1578-1585.
    http://rheumatology.oxfordjournals.org/content/53/9/1578.abstract
  • Unger L, Kampf S, Lüthke K, Aringer M.
    Rituximab therapy in patients with refractory dermatomyositis or polymyositis: differential effects in a real-life population
    Rheumatology (2014);53(9):1630-1638
    http://rheumatology.oxfordjournals.org/content/53/9/1630.abstract
  • Castro T, Lederman H, Terreri M, Caldana W, Zanoteli E, Hilário M.
    Whole-body magnetic resonance imaging in the assessment of muscular involvement in juvenile dermatomyositis/polymyositis patients.
    Scand J Rheumatol. 2014;43(4):329-33.
    http://www.ncbi.nlm.nih.gov/pubmed/25087579

AGOSTO 2014
  • Vercoulen Y, Bellutti Enders F, Meerding J, Plantinga M, Elst EF, Varsani H, van Schieveen C, Bakker MH, Klein M, Scholman RC, Spliet W, Ricotti V, Koenen HJ, de Weger RA, Wedderburn LR, van Royen-Kerkhof A, Prakken BJ.
    Increased Presence of FOXP3+ Regulatory T Cells in Inflamed Muscle of Patients with Active Juvenile Dermatomyositis Compared to Peripheral Blood.
    PLoS One. 2014 Aug 26;9(8):e105353. doi: 10.1371/journal.pone.0105353. eCollection 2014.
    http://www.ncbi.nlm.nih.gov/pubmed/25157414

JULIO 2014
  • Rider LG, Yip AL, Horkayne-Szakaly I, Volochayev R, Shrader JA, Turner ML, Kong HH, Jain MS, Jansen AV, Oddis CV, Fleisher TA, Miller FW.
    Novel assessment tools to evaluate clinical and laboratory responses in a subset of patients enrolled in the Rituximab in Myositis trial.
    Clin Exp Rheumatol. 2014 Jul 28. [Epub ahead of print]
    http://www.ncbi.nlm.nih.gov/pubmed/25068290
  • Schwartz T1, Sjaastad I2, Flatø B3, Vistnes M3, Christensen G4, Sanner H5.
    In active juvenile dermatomyositis, elevated eotaxin and MCP-1 and cholesterol levels in the upper normal range are associated with cardiac dysfunction.
    Rheumatology (Oxford). 2014 Jul 4. pii: keu256. [Epub ahead of print]
    http://www.ncbi.nlm.nih.gov/pubmed/24996906
  • Boccaletti V1, Di Nuzzo S, Feliciani C, Fabrizi G, Pagliarello C.
    An update on juvenile dermatomyositis.
    G Ital Dermatol Venereol. 2014 Jul 18. 
    http://www.ncbi.nlm.nih.gov/pubmed/25034096
  • Singh S1, Suri D, Aulakh R, Gupta A, Rawat A, Kumar RM.
    Mortality in children with juvenile dermatomyositis: two decades of experience from a single tertiary care centre in North India.
    Clin Rheumatol. 2014 Jul 23.
    http://www.ncbi.nlm.nih.gov/pubmed/25053380
  • Yu HH1, Chang HM2, Chiu CJ3, Yang YH1, Lee JH1, Wang LC1, Lin YT1, Chiang BL4.
    Detection of anti-p155/140, anti-p140, and antiendothelial cells autoantibodies in patients with juvenile dermatomyositis.
    J Microbiol Immunol Infect. 2014 Jul 25. 
    http://www.ncbi.nlm.nih.gov/pubmed/25070283
  • McCann LJ1, Arnold K2, Pilkington CA3, Huber AM4, Ravelli A5, Beard L2, Beresford MW6, Wedderburn LR7.
    Developing a provisional, international Minimal Dataset for Juvenile Dermatomyositis: for use in clinical practice to inform research.
    Pediatr Rheumatol Online J. 2014 Jul 21;12:31. doi: 10.1186/1546-0096-12-31. eCollection 2014.
    http://www.ncbi.nlm.nih.gov/pubmed/25075205
  • Tansley SL1, Betteridge ZE1, Shaddick G1, Gunawardena H1, Arnold K2, Wedderburn LR2, McHugh NJ3; on behalf of the Juvenile Dermatomyositis Research Group.
    Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset.
    Rheumatology (Oxford). 2014 Jul 1. pii: keu259. [Epub ahead of print]
    http://www.ncbi.nlm.nih.gov/pubmed/24987158
  • Tansley SL, Betteridge ZE, Gunawardena H, Jacques TS, Owens CM, Pilkington C, Arnold K, Yasin S, Moraitis E, Wedderburn LR, McHugh NJ.
    Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study.
    Arthritis Res Ther. 2014 Jul 2;16(4):R138. [Epub ahead of print]
    http://www.ncbi.nlm.nih.gov/pubmed/24989778
  • Rheumatology (Oxford). 2014 Jul 1. pii: keu259. [Epub ahead of print]
    Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset.
    Tansley SL1, Betteridge ZE1, Shaddick G1, Gunawardena H1, Arnold K2, Wedderburn LR2, McHugh NJ3; on behalf of the Juvenile Dermatomyositis Research Group.
    http://www.ncbi.nlm.nih.gov/pubmed/24987158
  • Tansley SL, Betteridge ZE, Gunawardena H, Jacques TS, Owens CM, Pilkington C, Arnold K, Yasin S, Moraitis E, Wedderburn LR, McHugh NJ.
    Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study.
    Arthritis Res Ther. 2014 Jul 2;16(4):R138. [Epub ahead of print]
    http://www.ncbi.nlm.nih.gov/pubmed/24989778

JUNIO 2014
  • Fujisawa T, Hozumi H, Kono M, Enomoto N, Hashimoto D, Nakamura Y, Inui N, Yokomura K, Koshimizu N, Toyoshima M, Shirai T, Yasuda K, Hayakawa H, Suda T.
    Prognostic factors for myositis-associated interstitial lung disease
    PLoS One. 2014 Jun 6;9(6):e98824. doi: 10.1371/journal.pone.0098824. eCollection 2014.
    http://www.ncbi.nlm.nih.gov/pubmed/24905449
  • Neri R, Barsotti S, Iacopetti V, Tripoli A, dʼAscanio A, Tavoni AG, Mosca M, Bombardieri S.
    Clinically amyopathic dermatomyositis: analysis of a monocentric cohort.
    J Clin Neuromuscul Dis. 2014 Jun;15(4):157-60. doi: 10.1097/CND.0000000000000038.
    http://www.ncbi.nlm.nih.gov/pubmed/24872214

MAYO2014
  • Valenzuela A, Chung L, Casciola-Rosen L, Fiorentino D.
    Identification of Clinical Features and Autoantibodies Associated With Calcinosis in Dermatomyositis.
    JAMA Dermatol. 2014 May 28. doi: 10.1001/jamadermatol.2013.10416. [Epub ahead of print]
  • Article in French
    Pouessel G1, Thumerelle C2, Nève V3, Santangelo T4, Flammarion S1, Pruvot I5, Tillie-Leblond I6, Deschildre A7.
    Lung is also involved in juvenile dermatomyositis.
    Rev Med Interne. 2014 May 21.[Epub ahead of print]
    http://www.ncbi.nlm.nih.gov/pubmed/24856457

MARZO 2014
  • Robinson AB1, Hoeltzel MF, Wahezi DM, Becker ML, Kessler EA, Schmeling H, Carrasco R, Huber AM, Feldman BM, Reed AM; Juvenile Myositis CARRA Subgroup, for the CARRA Registry Investigators.
    Clinical characteristics of children with juvenile dermatomyositis: the childhood arthritis and rheumatology research alliance registry.
    Arthritis Care Res (Hoboken). 2014 Mar;66(3):404-10. doi: 10.1002/acr.22142.
    http://www.ncbi.nlm.nih.gov/pubmed/23983017
  • Aggarwal R1, Bandos A, Reed AM, Ascherman DP, Barohn RJ, Feldman BM, Miller FW, Rider LG, Harris-Love MO, Levesque MC; RIM Study Group, Oddis CV.
    Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis.
    Arthritis Rheumatol. 2014 Mar;66(3):740-9. doi: 10.1002/art.38270.
    http://www.ncbi.nlm.nih.gov/pubmed/24574235

FEBRERO 2014
  • McCrea N, Al-Sabbagh A, Ahmed S, Walker D, Rangaraj S.
    Onset of juvenile dermatomyositis following varicella infection in a 12-month-old child: a case report.
    J Med Case Rep. 2014 Feb 15;8(1):54. [Epub ahead of print]
    http://www.ncbi.nlm.nih.gov/pubmed/24529167

DICIEMBRE 2013
  • Mamyrova G, Katz JD, Jones RV, Targoff IN, Lachenbruch PA, Jones OY, Miller FW, Rider LG; Childhood Myositis Heterogeneity Collaborative Study Group.
    Clinical and laboratory features distinguishing juvenile polymyositis and muscular dystrophy.
    Arthritis Care Res (Hoboken). 2013 Dec;65(12):1969-75. doi: 10.1002/acr.22088.
    http://www.ncbi.nlm.nih.gov/pubmed/23925923

NOVIEMBRE 2013

OCTUBRE 2013
  • Huber AM, Mamyrova G, Lachenbruch PA, Lee JA, Katz JD, Targoff IN, Miller FW, Rider LG; for the Childhood Myositis Heterogeneity Study Group.
    Early Illness Features Associated with Mortality in The Juvenile Idiopathic Inflammatory Myopathies.
    Arthritis Care Res (Hoboken). 2013 Oct 21.[Epub ahead of print]
    http://www.ncbi.nlm.nih.gov/pubmed/24151254

SEPTIEMBRE 2013
  • Prestridge A, Morgan G, Ferguson L, Huang CC, Pachman LM.
    Pulmonary Function Tests in Idiopathic Inflammatory Myopathy: Association With Clinical Parameters in Children
    Arthritis Care Res 2013 Sep; 65(9):1424-31.
    http://onlinelibrary.wiley.com/doi/10.1002/acr.22014/abstract
  • Robinson AB, Hoeltzel MF, Wahezi DM, Becker ML, Kessler E, Schmeling H, Carrasco R, Huber AM, Feldman BM, Reed AM; Juvenile Myositis CARRA Subgroup; CARRA Registry Investigators.
    Clinical characteristics of children with juvenile dermatomyositis - the children's arthritis and rheumatology research alliance (CARRA) registry.
    Arthritis Care Res (Hoboken). 2013 Aug 27. doi: 10.1002/acr.22142. [Epub ahead of print]

JULIO 2013
  • Martillotti J, Moote D, Zemel L.
    Improvement of calcinosis using pamidronate in a patient with juvenile dermatomyositis.
    Pediatr Radiol. 2013 Jul 10. [Epub ahead of print]

MAYO 2013
  • Malattia C, Damasio MB, Madeo A, Pistorio A, Providenti A, Pederzoli S, Viola S, Buoncompagni A, Mattiuz C, Beltramo A, Consolaro A, Ravelli A, Ruperto N, Picco P, Magnano GM, Martini A
    Whole-body MRI in the assessment of disease activity in juvenile dermatomyositis
    Ann Rheum Dis 2013 May 1. [Epub ahead of print]
    http://www.ncbi.nlm.nih.gov/pubmed/23636654
  • Quiñones R, Morgan GA, Amoruso M, Field R, Huang CC, Pachman LM.
    Four-year-olds, healthy or recovering from Juvenile Dermatomyositis, do not achieve a full score on the Childhood Myositis Assessment Scale (CMAS).
    Arthritis Care Res (Hoboken) 2013 May 10:NA. doi: 10.1002/acr.22041. [Epub ahead of print]
    http://www.ncbi.nlm.nih.gov/pubmed/23666925
  • Shah M, Targoff IN, Rice MM, Miller FW, Rider LG; with the Childhood Myositis Heterogeneity Collaborative Study Group.
    Ultraviolet radiation exposure is associated with clinical and autoantibody phenotypes in Juvenile Myositis.
    Arthritis Rheum 2013 May 8. doi: 10.1002/art.37985. [Epub ahead of print]
    http://www.ncbi.nlm.nih.gov/pubmed/23658122
  • Lazarevic D, Pistorio A, Palmisani E, Miettunen P, Ravelli A, Pilkington C, Wulffraat NM, Malattia C, Garay SM, Hofer M, Quartier P, Dolezalova P, Penades IC, Ferriani VP, Ganser G, Kasapcopur O, Melo-Gomes JA, Reed AM, Wierzbowska M, Rider LG, Martini A, Ruperto N; Paediatric Rheumatology International Trials Organisation (PRINTO).
    The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis
    Ann Rheum Dis. 2013 May;72:686-93. doi: 10.1136/annrheumdis-2012-201483.
    http://www.ncbi.nlm.nih.gov/pubmed/22736096

FEBRERO 2013
  • Mathiesen PR, Ørngreen MC, Vissing J, Andersen LB, Herlin T, Nielsen S.
    Aerobic fitness after JDM--a long-term follow-up study.
    Rheumatology (Oxford). 2013 Feb;52(2):287-95. doi: 10.1093/rheumatology/kes232. Epub 2012 Sep 22.
    http://www.ncbi.nlm.nih.gov/pubmed/23001614
  • Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC, Barohn RJ, Feldman BM, Harris-Love MO, Koontz DC, Fertig N, Kelley SS, Pryber SL, Miller FW, Rockette HE for the Rituximab in Myositis (RIM) Study Group.
    Rituximab in the treatment of refractory adult and juvenile dermatomiositis and adult polymyositis: A randomized, placebo-phase trial.
    Arthritis Rheum. 2013 Feb;65(2):314-24. doi: 10.1002/art.37754.

ENERO 2013
  • Shah M, Mamyrova G, Targoff IN, Huber AM, Malley JD, Rice MM, Miller FW, Rider LG; with the Childhood Myositis Heterogeneity Collaborative Study Group.
    The Clinical Phenotypes of the Juvenile Idiopathic Inflammatory Myopathies.
    Medicine (Baltimore). 2013 Jan;92(1):25-41.
    http://www.ncbi.nlm.nih.gov/pubmed/23263716

DICIEMBRE 2012
  • Pouessel G, Deschildre A, Le Bourgeois M, Cuisset JM, Catteau B, Karila C, Nève V, Thumerelle C, Quartier P, Tillie-Leblond I.
    The lung is involved in juvenile dermatomyositis.
    Pediatr Pulmonol. 2012 Dec 31. doi: 10.1002/ppul.22742. [Epub ahead of print]
    http://onlinelibrary.wiley.com/doi/10.1002/ppul.22742/pdf
  • Reed AM, Peterson E, Bilgic H. Ytterberg SR, Amin S, Hein MS, Crowson CS, Ernste F, Gillespie EB.
    Changes in novel biomarkers of disease activity in juvenile and adult dermatomyositis are sensitive biomarkers of disease course.
    Arthritis Rheum 2012 Dec; 64(12):4078–86. DOI: 10.1002/art.34659.
    http://onlinelibrary.wiley.com/doi/10.1002/art.34659/abstract

SEPTIEMBRE 2012
  • Patwardhan A, Rennebohm RM, Dvorchik I, Spencer CH.
    Is juvenile dermatomiositis a different disease in children up to three years of age at onset than in children above three years at onset? A retrospective review of 23 years of single center experience.
    Pediatr Rheumatol Online J. 2012 Sep 20;10(1):34. [Epub ahead of print].
    http://www.ncbi.nlm.nih.gov/pubmed/22995763


ABRIL 2012
  • Huber AM, Robinson AB, Reed AM, Abramson L, Bout-Tabaku S, Carrasco R, Curran M, Feldman BM, Gewanter H, Griffin T, Haines K, Hoeltzel MF, Isgro J, Kahn P, Lang B, Lawler P, Shaham B, Schmeling H, Scuccimarri R, Shishov M, Stringer E, Wohrley J, Ilowite NT, Wallace C; Juvenile Dermatomyositis Subcommittee of the Childhood Arthritis and Rheumatology Research Alliance.
    Consensus treatments for moderate juvenile dermatomyositis: beyond the first two months. Results of the second Childhood Arthritis and Rheumatology Research Alliance consensus conference.
    Arthritis Care Res (Hoboken). 2012 Apr;64(4):546-53. doi: 10.1002/acr.20695.
    http://www.ncbi.nlm.nih.gov/pubmed/22076847
PATROCINADORES

Área de Socios